Special Issue

Recent Research on Dry Eye

Message from the Guest Editor

This Special Issue aims to explore the latest advancements in our understanding of the pathophysiology of dry eye, including risk and protective factors, and possible therapeutic solutions. We invite submissions that cover a broad range of topics, including but not limited to the biochemical changes in tear film composition, innovative diagnostic techniques, and novel therapeutic interventions. Our goal is to compile a collection of high-quality research articles, reviews, and brief reports that not only deepen our understanding of these conditions but also contribute to the development of effective strategies for prevention, diagnosis, and treatment. We encourage contributions from researchers whose work helps bridge the gap between basic science and clinical practice in the study of dry eye. We look forward to your submissions, advancing our knowledge of these increasingly prevalent conditions, which have significant implications for ocular and general health worldwide.

Guest Editor

Dr. Liat Gantz

Department of Optometry and Vision Science, Hadassah Academic College, Jerusalem, Israel

Deadline for manuscript submissions

30 September 2025



an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/231743

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).